宁波优贝德产品网站Unibest
← Back to patent-cliff list

Rimiducid

Tier C — Watch / trade

Rimiducid

Ariad Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:FKBP1A

Indications (approved):大B细胞淋巴瘤, Hodgkin's disease, Non-Hodgkin lymphoma, 骨硬化症, 血红蛋白病, 血细胞减少症, 原发性免疫缺陷疾病, Aplastic anaemia

Regional status

US
Phase II
2013-03-01
EU
Phase I
2018-02-01
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 10 · Total yield 5.49 g
RIMI-001951-82-6RIMI-002195202-06-3RIMI-003102029-44-7RIMI-004—RIMI-005195202-08-5RIMI-00690710-04-6RIMI-007195202-09-6RIMI-008178445-89-1RIMI-009195202-26-7RIMI-010120-14-9RIMI-011121-71-1RIMI-012215168-57-3RIMI-013178445-83-5RIMI-014178445-86-8API · Rimiducid
CodeCAS No.Intermediate
RIMI-001951-82-62-(3,4,5-trimethoxyphenyl)acetic acid
RIMI-002195202-06-32-(3,4,5-trimethoxyphenyl)butanoic acid
RIMI-003102029-44-7Available(R)-4-benzyloxazolidin-2-one
RIMI-004-(4R)-4-benzyl-3-(2-(3,4,5-trimethoxyphenyl)butanoyl)oxazolidin-2-one
RIMI-005195202-08-5(S)-2-(3,4,5-trimethoxyphenyl)butanoic acid
RIMI-00690710-04-6methyl (S)-piperidine-2-carboxylate
RIMI-007195202-09-6(S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylic acid
RIMI-008178445-89-1tert-butyl (R)-2-(3-(3-(3,4-dimethoxyphenyl)-1-hydroxypropyl)phenoxy)acetate
RIMI-009195202-26-7(R)-1-(3-(2-(tert-butoxy)-2-oxoethoxy)phenyl)-3-(3,4-dimethoxyphenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate
RIMI-010120-14-93,4-dimethoxybenzaldehyde
RIMI-011121-71-11-(3-hydroxyphenyl)ethan-1-one
RIMI-012215168-57-3(E)-3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one
RIMI-013178445-83-53-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)propan-1-one
RIMI-014178445-86-8tert-butyl 2-(3-(3-(3,4-dimethoxyphenyl)propanoyl)phenoxy)acetate

Frequently asked questions

What are the approved indications of Rimiducid?

Approved indications include: 大B细胞淋巴瘤, Hodgkin's disease, Non-Hodgkin lymphoma, 骨硬化症, 血红蛋白病, 血细胞减少症, 原发性免疫缺陷疾病, Aplastic anaemia.

When does the Rimiducid patent expire?

No public expiry year is available for Rimiducid yet; this page updates once verified.

How many synthesis routes are recorded for Rimiducid?

1 synthesis routes are recorded; the shortest is 10 steps with 5.49 g total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Rimiducid intermediates?

1 intermediate CAS of Rimiducid are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Rimiducid intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-13